Eli Lilly

News

Lilly sets aside $2.1bn for domestic investments

Eli Lilly's home state of Indiana is set to benefit from a massive $2.1 billion investment by the pharma group, earmarked for two brand new manufacturing facilities.

News

Second trial opens door for Lilly's mirikizumab in ulcerativ...

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory review

News

CHMP backs Sanofi's Xenpozyme as first drug for ASMD

Sanofi's Genzyme unit has moved a step closer to securing EU approval for Xenpozyme – its enzyme replacement therapy for rare disease acid sphingomyelinase deficiency (ASMD) – after scoring

News

Insulin producers face fresh lawsuit in US over pricing

Arkansas has become the latest US state to issue a legal challenge to the big three insulin producers – Eli Lilly, Sanofi and Novo Nordisk – accusing them of deceptively driving up the pric

News

AZ bites back at rivals with new Farxiga data in heart failu...

AstraZeneca's SGLT2 inhibitor Farxiga has hit the mark in a phase 3 heart failure trial that brings it back into contention with its main rival Jardiance from Boehringer Ingelheim and Eli L

News

Lilly fires a broadside at Novo Nordisk's obesity ambitions

Denmark's Novo Nordisk has been almost single-handedly rebuilding the market for drugs to treat obesity over the last few years with its GLP-1 agonist drugs

Lilly sets aside $2.1bn for domestic investments

Second trial opens door for Lilly's mirikizumab in ulcerativ...

CHMP backs Sanofi's Xenpozyme as first drug for ASMD

Insulin producers face fresh lawsuit in US over pricing

AZ bites back at rivals with new Farxiga data in heart failu...

Lilly fires a broadside at Novo Nordisk's obesity ambitions

NICE changes stance on Genmab's cervical cancer drug

Discover a new era of healthcare panel engagement: Grounded ...

Eli Lilly

Editor's Picks